Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $77.40 and last traded at $77.40, with a volume of 100 shares trading hands. The stock had previously closed at $64.70.
Basilea Pharmaceutica Stock Performance
The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $62.17 and a 200-day moving average of $66.76.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- SK hynix Triggers $28B Defense Against Tech Selloff
- Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
